Treatment-related adverse events of special interest | Number of events | Outcome, n (%) | Action taken, n (%) | ||||||
---|---|---|---|---|---|---|---|---|---|
Resolved | Improved | Persistent | Led to death | Unknown | Temporary interruption | Dose reduction | Permanent discontinuation | ||
Hypertension | 1582 | 895 (57%) | 221 (14%) | 449 (28%) | 0 | 17 (1%) | 84 (5%) | 39 (2%) | 15 (1%) |
Proteinuria | 933 | 477 (51%) | 95 (10%) | 353 (38%) | 0 | 8 (1%) | 112 (12%) | 31 (3%) | 22 (2%) |
Hand-foot syndrome | 400 | 205 (51%) | 55 (14%) | 139 (35%) | 0 | 1 (< 1%) | 98 (25%) | 36 (9%) | 15 (4%) |
Bleeding | 784 | 477 (61%) | 39 (5%) | 227 (29%) | 27 (3%) | 14 (2%) | 75 (10%) | 10 (1%) | 83 (11%) |
Hepatotoxicity | 1464 | 616 (42%) | 147 (10%) | 658 (45%) | 6 (< 1%) | 37 (3%) | 105 (7%) | 21 (1%) | 55 (4%) |
Cardiac toxicity | 56 | 36 (64%) | 3 (5%) | 17 (30%) | 0 | 0 | 10 (18%) | 0 | 2 (4%) |